BioSpace News Archive

Otsuka Medical Devices Co., Ltd. (OMD) a subsidiary of Otsuka Holdings, Inc., and its subsidiary, ReCor Medical, Inc. (“ReCor”), today announced that the findings from the REQUIRE trial of ReCor’s Paradise™ Ultrasound Renal Denervation System for the treatment of hypertension conducted in Japan and Korea were presented at the Japanese Society of Hypertension (JSH) meeting.

Treadwell Therapeutics today announced the acquisition of TCRyption Inc., a company focusing on novel approaches to TCR based T cell therapy and a TIO Bioventures portfolio company.

Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc. (SpinaFX), is pleased to announce the appointment of John Soloninka as Chief Operating Officer.

PENTAX Medical is pleased to announce it has expanded its contract with Vizient to include pediatric endoscopic solutions.

Paige Announces Presentations and Exhibit Booth at Pathology Visions 2021 Conference

Oncology Pharma Inc. (OTC PINK:ONPH) Pursuant to previously announced press release, Oncology Pharma, Inc. has retained the services of DBBMcKennon, LLC, a PCAOB Certified Public Accounting Firm.

The engineering run will provide the Company with a batch of its lead drug candidate MB-204 that can be used in good laboratory practise (“GLP”) toxicology studies, which are scheduled to begin in Q4 2021.

Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the “Company”), a leader in the public cloud for Hospitals, Health Systems and Life Sciences, today announced the closing of its initial public offering of 3,262,500 shares of common stock (the “Common Stock”) at a public offering price of $4.00 per share.

Seqirus today announced that the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX® QUADRIVALENT

Genentech today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for adults with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1≥1%, as determined by an FDA-approved test.